Cost–Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China

被引：0
|
作者：
Jian Ming
Yuxia Wu
Rong Han
Xing Xu
Reg Waldeck
Shanlian Hu
机构：
[1] IQVIA China,Real World Solutions
[2] Bayer Healthcare Company Ltd,Medical Affairs, Pharmaceuticals
[3] Bayer Healthcare Pharmaceuticals,School of Public Health
[4] Fudan University,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Cost-utility analysis; Darolutamide; Novel androgen receptor inhibitors; Non-metastatic castration-resistant prostate cancer; nmCRPC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1087 / 1103
页数：16
相关论文
共 50 条
  • [1] Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China
    Ming, Jian
    Wu, Yuxia
    Han, Rong
    Xu, Xing
    Waldeck, Reg
    Hu, Shanlian
    ADVANCES IN THERAPY, 2023, 40 (03) : 1087 - 1103
  • [2] A MODELED HEALTH OUTCOMES EVALUATION OF DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY FOR HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHINA
    Ming, J.
    Liu, Y.
    Lu, W.
    Wu, Y.
    Li, W.
    Han, R.
    Hu, S.
    VALUE IN HEALTH, 2021, 24 : S2 - S2
  • [3] Darolutamide for non-metastatic, castration-resistant prostate cancer
    Burki, Talha
    LANCET ONCOLOGY, 2019, 20 (03): : E139 - E139
  • [4] A new androgen receptor antagonist Darolutamide for patients with non-metastatic castration-resistant prostate cancer
    Kesch, C.
    Hadaschik, B. A.
    UROLOGE, 2019, 58 (10): : 1217 - 1218
  • [5] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2020, 15 (06) : 791 - 799
  • [6] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Targeted Oncology, 2020, 15 : 791 - 799
  • [7] Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide
    Fujmoto, Saizo
    Fujita, Kazutoshi
    Nishimoto, Mitsuhisa
    Hamaguchi, Mamoru
    Kuwahara, Ken
    Hashimoto, Mamoru
    Adomi, Shogo
    Minami, Takafumi
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    CANCER MEDICINE, 2023, 12 (03): : 3176 - 3179
  • [8] COST-EFFECTIVENESS ANALYSIS OF DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH HIGH- RISK NON-METASTATIC CASTRATIONRESISTANT PROSTATE CANCER IN CHINA
    Ming, J.
    Wu, Y.
    Han, L.
    Xu, X.
    Waldeck, R.
    Hu, S.
    VALUE IN HEALTH, 2022, 25 (12) : S85 - S86
  • [9] Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Targeted Oncology, 2022, 17 : 381 - 381
  • [10] Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer
    Iwamoto, Hiroaki
    Kano, Hiroshi
    Shimada, Takafumi
    Naito, Renato
    Makino, Tomoyuki
    Kadamoto, Suguru
    Yaegashi, Hiroshi
    Shigehara, Kazuyoshi
    Izumi, Kouji
    Kadonoa, Yoshifumi
    Mizokami, Atsushi
    IN VIVO, 2021, 35 (02): : 1247 - 1252
12345